Serologic response to COVID-19 vaccines could be mounted in patients with IBD; however, its magnitude was significantly lower in patients treated with anti-tumor necrosis factor α (anti-TNF) agents regardless of administration timing and drug levels [26,27,28,29]. The gene discussed is TNF; the disease is inflammatory bowel disease.